Tubulins as therapeutic targets in cancer: from bench to bedside
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F12%3A00387835" target="_blank" >RIV/68378050:_____/12:00387835 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.2174/138161212800626193" target="_blank" >http://dx.doi.org/10.2174/138161212800626193</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/138161212800626193" target="_blank" >10.2174/138161212800626193</a>
Alternative languages
Result language
angličtina
Original language name
Tubulins as therapeutic targets in cancer: from bench to bedside
Original language description
Tubulin is the target of some of the most widely used and time-honored anticancer tubulin-binding agents (TBAs). The clinical usefulness of many TBAs has been held back as a result of tumor cell drug-resistance. The elucidation of the three-dimensional structure of alpha beta-tubulin dimer has provided an opportunity for rational drug design aimed at generating compounds that will target tubulin in therapeutically more efficacious ways compared to presently available drugs. An issue to be addressed is which one(s) of the tubulin species, their isotypes, or their posttranslationally modified forms, should be specifically targeted in cancer chemotherapy. This review offers a critical appraisal of current knowledge on tubulins in cancer and an update on new anti-neoplastic microtubule-targeted treatment strategies. Specifically, it examines, across disciplines, cellular/molecular, biochemical, clinical/pathological, and pharmacological aspects of beta-tubulin isotypes, posttranslational m
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EB - Genetics and molecular biology
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current Pharmaceutical Design
ISSN
1381-6128
e-ISSN
—
Volume of the periodical
18
Issue of the periodical within the volume
19
Country of publishing house
GB - UNITED KINGDOM
Number of pages
15
Pages from-to
2778-2792
UT code for WoS article
000306546900010
EID of the result in the Scopus database
—